Important COVID-19 Updates
Providing solutions to critical research and development needs
COVID-19 has highlighted the lifesaving value of accelerated vaccine and therapeutic development. Virscio is uniquely positioned to generate preclinical data to propel your program to clinic.
Enabling access to critical research resources: St. Kitts green monkeys
Nonhuman primates offer predictive advantages over other test species. Immunologic, anatomic and genetic homology to humans contribute to similar response to pathogens and vaccines, positioning the St. Kitts green monkey as a robust model to evaluate immunogenicity, reactogenicity, safety, biodistribution and pharmacodynamics of candidates.
Accelerated COVID-19 program support
Our scientific team is actively supporting development of SARS-CoV-2 vaccines and therapeutics targeting Acute Respiratory Distress Syndrome and related pathologies in study designs appropriate to our BSL2 facilities. While we do not engage in live SARS-CoV-2 virus challenge studies we are well-equipped and positioned to evaluate critical biological behavior of candidates, including:
- Pharmacokinetics & pharmacodynamics
- Safety and tolerability (GLP and non-GLP)
Ensuring safety and reducing risk for employees, animals, programs and clients
Virscio maintains full scientific operations and is committed to doing so to ensure both continuity of Sponsor research and development programs and the safety of our employees and nonhuman primate research resources. We have extended universal precautions – a standard component of our nonhuman primate husbandry – to all aspects our operations, implemented social distancing procedures and scheduling, and further secured our facility’s unique biological isolation. We have additionally remained actively engaged with government authorities to promote best practices within our community and with courier and broker services to maintain uninterrupted supply lines and test article and sample shipments.